Cholesterol Absorption Inhibitor – Pipeline Insight, 2019 –

Absorption Inhibitor – Pipeline Insight, 2019”
drug pipelines
has been added to’s offering.

Cholesterol Absorption Inhibitor – Pipeline Insight, 2019
offers comprehensive insights of the pipeline (under development)
therapeutics scenario and growth prospects across Cholesterol Absorption
Inhibitor development.

The report provides detailed coverage of the pipeline landscape for this
mechanism of action, equipped with data from multiple sources with
complete pipeline analysis by developmental stage, associated
indications, route of administration and molecule type.

Pipeline Products covered across the following Developmental

  • Clinical
  • Non-clinical
  • Inactive: Discontinued and/or Dormant

Pipeline therapeutics development coverage provides descriptive product
profiles including (but not limited to) drug description, product
development and R&D activities encompassing clinical and pre-clinical
studies, designations, collaborations, licensing deals, grants,
technologies and patent details.

Scope of the Report

  • Provides a snapshot of the therapeutics pipeline activity for
    Cholesterol Absorption Inhibitor
  • Features the Cholesterol Absorption Inhibitor pipeline across the
    complete product development cycle including all clinical and
    non-clinical stages
  • Offers detailed therapeutic product profiles of Cholesterol Absorption
    Inhibitor with key coverage of developmental activities including
    licensing & collaboration deals, patent details, designations,
    technologies, indications and chemical information
  • Therapeutic assessment of the active pipeline products by stage,
    product type, molecule type, and route of administration
  • Coverage of dormant and discontinued pipeline projects across
    Cholesterol Absorption Inhibitor

Reasons to Buy

  • Establish a comprehensive understanding of the current pipeline
    scenario across Cholesterol Absorption Inhibitor to formulate
    effective R&D strategies
  • Assess challenges and opportunities that influence Cholesterol
    Absorption Inhibitor research & development (R&D)
  • Gather impartial perspective of strategies of the emerging competitors
    having potentially lucrative portfolio in this space and create
    effective counter strategies to gain competitive advantage
  • Identify and understand the sought after therapy areas and indications
    for Cholesterol Absorption Inhibitor
  • Identify the product attributes and use it for target finding, drug
    repurposing, and precision medicine
  • Devise in licensing and out licensing strategies by identifying
    prospective partners with progressing projects for Cholesterol
    Absorption Inhibitor to enhance and expand business potential and scope
  • Plan prospective mergers and acquisitions effectively by identifying
    key players in this area and their most promising pipeline
    therapeutics and developmental progress

Topics Covered

1. Report Introduction

2. Cholesterol Absorption Inhibitor – Overview

3. Pipeline Therapeutics

  • An Overview of Pipeline Products for Cholesterol Absorption Inhibitor

4. Comparative Analysis

5. Cholesterol Absorption Inhibitor Pipeline Products in
Clinical Stages

  • Product Description
  • Research and Development
  • Product Development Activities

6. Cholesterol Absorption Inhibitor Pipeline Products in
Non-clinical Stages

  • Product Description
  • Research and Development
  • Product Development Activities

7. Therapeutic Assessment: Active Products

  • Pipeline Assessment by Route of Administration
  • Pipeline Assessment by Stage and Route of Administration
  • Pipeline Assessment by Molecule Type
  • Pipeline Assessment by Stage and Molecule Type

8. Inactive Pipeline Products

  • Product Description
  • Research and Development
  • Product Development Activities
  • Reason for dormancy/discontinuation

Companies Mentioned

  • Schering-Plough
  • Kotobuki Pharmaceutical
  • Lipideon Biotechnology AG
  • AstraZeneca
  • AtheroNova
  • Esperion Therapeutics
  • Zhejiang Hisun Pharmaceutical
  • Merck
  • DreamPharma Corporation

For more information about this drug pipelines report visit

Laura Wood, Senior Press Manager
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
For GMT Office Hours Call +353-1-416-8900
Topics: Cardiovascular